A Phase 1 interventional study of PDR001 in Parkinson Disease (PD), sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Ruijin Hospital · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Parkinson Disease by Ruijin Hospital — 8 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · Ruijin Hospital.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1, and was the 16th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →8 of the 20 studies in Parkinson Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 50–85
Ruijin Hospital · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ruijin Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Ruijin Hospital · Sites in China
Ages 40–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 29 across the 18 interventional studies, 360 across the 2 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
2 of the studies in Parkinson Disease by Ruijin Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07353463Ruijin HospitalShanghai Clinical Cohort - Parkinson's Disease (Reserve) | 2026-12-31 |
| NCT07774312Ruijin HospitalSTN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary drivers of PD pathogenesis. While siRNA-mediated knockdown of α-synuclein can offer some protection to dopaminergic neurons, its clinical utility is hampered by low cellular uptake, off-target effects, and transient activity. These drawbacks underscore the urgent need for novel strategies that can efficiently and specifically degrade α-synuclein to delay or even halt PD progression.
Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein. When packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus, this peptide effectively reduces α-synuclein within the target region. Pre-clinical studies in both human-α-synuclein-expressing mice and non-human primate models of PD have demonstrated robust α-synuclein clearance and marked improvements in motor deficits (see Research Foundation).
The present project will advance PDR-001 into first-in-human studies to evaluate safety and explore preliminary efficacy. Unlike conventional symptomatic therapies, this approach targets the root cause of PD, setting the stage for disease-modifying treatment. Successful translation would establish a new therapeutic paradigm capable of slowing or preventing PD progression.
Inclusion Criteria:
To be eligible for inclusion in this clinical study, all of the following criteria must be met:
Exclusion Criteria:
Exclusion Criteria
Positive screening for infectious diseases:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PDR-001 injection, inject once, 0.4 milliliters each time
Drug: PDR001
This drug was packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus
PDR-001 treatment-related adverse events as assessed by CTCAE v5.0
CTCAE 5.0 records the severity of adverse events, which is divided into grades 1 to 5
Time frame: From enrollment to the end of treatment at 52 weeks
Titer levels of capsid neutralizing antibodies and binding antibodies against recombinant adeno-associated virus (rAAV) in serum
Record the titer changes before and after treatment
Time frame: From enrollment to the end of treatment at 52 weeks
Titer of rAAV vectors in whole blood
Record the titer changes before and after treatment
Time frame: From enrollment to the end of treatment at 52 weeks
Evaluation of the use of antiparkinsonian drugs will be assessed using the Levodopa Equivalent Daily Dose (LEDD)
The total daily dose of antiparkinsonian medication (converted to LEDD, mg/day) will be calculated and compared before and after treatment. A decrease in LEDD indicates reduced drug burden (better outcome), while an increase indicates greater drug requirement (worse outcome).
Time frame: From enrollment to the end of treatment at 52 weeks
Treatment efficacy will be evaluated using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
This scale has a total score range of 0 to 260, with higher scores indicating more severe motor and non-motor symptoms (worse outcome). Changes in scores before and after treatment will be recorded.
Time frame: From enrollment to the end of treatment at 52 weeks
Treatment efficacy will be evaluated using the Patient Global Impression - Improvement scale (PGI-I)
This is a 7-point scale ranging from 1 ("very much improved") to 7 ("very much worse"), with lower scores indicating greater improvement (better outcome). Changes in scores before and after treatment will be recorded.
Time frame: From enrollment to the end of treatment at 52 weeks
Treatment efficacy will be evaluated using the Clinical Global Impression - Improvement scale (CGI-I)
This is a 7-point scale ranging from 1 ("very much improved") to 7 ("very much worse"), with lower scores indicating greater clinical improvement (better outcome). Changes in scores before and after treatment will be recorded.
Time frame: From enrollment to the end of treatment at 52 weeks
Treatment efficacy will be evaluated using the Mini-Mental State Examination (MMSE)
The total score ranges from 0 to 30, with higher scores indicating better cognitive function (better outcome). Changes in scores before and after treatment will be recorded.
Time frame: From enrollment to the end of treatment at 52 weeks
Treatment efficacy will be evaluated using the Hamilton Depression Rating Scale (HAM-D, 17-item version)
The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms (worse outcome). Changes in scores before and after treatment will be recorded.
Time frame: From enrollment to the end of treatment at 52 weeks
Change in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAM-A)
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale with scores ranging from 0 to 56, where higher scores indicate greater severity of anxiety symptoms. Treatment efficacy will be evaluated by the change in HAM-A total score from baseline to 52 weeks
Time frame: From enrollment to the end of treatment at 52 weeks
Change in sleep-related problems as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2)
PDSS-2 is a 15-item questionnaire. The total score ranges from 0 to 60, with higher scores indicating worse sleep-related problems. Treatment efficacy will be evaluated by the changes in PDSS-2 from baseline to 52 weeks
Time frame: From enrollment to the end of treatment at 52 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Oct 2025; primary completion for Jan 2029, 39 months later.
Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 39 months is close to that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spartalizumab